A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs AST 008 (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Exicure
- 07 Nov 2019 According to the Exicure media release, the preliminary results from phase Ib is expected in december 2019.
- 07 Nov 2019 According to the Exicure media release, as of 1 November 2019, 13 patients in the first four cohorts of the phase Ib stage have been dosed.
- 12 Aug 2019 Planned number of patients changed from 81 to 130.